Inhibition of Angiogenesis by Thalidomide Requires Metabolic Activation, Which Is Species-dependent
- 24 June 1998
- journal article
- research article
- Published by Elsevier BV in Biochemical Pharmacology
- Vol. 55 (11), 1827-1834
- https://doi.org/10.1016/s0006-2952(98)00046-x
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- A reversed-phase high performance liquid chromatography method using solid phase extraction to quantitate thalidomide in human serumAnalytica Chimica Acta, 1997
- Angiogenesis as a Predictor of Long-term Survival for Patients With Node-Negative Breast CancerJNCI Journal of the National Cancer Institute, 1996
- Patterns and Emerging Mechanisms of the Angiogenic Switch during TumorigenesisCell, 1996
- Thalidomide promotes metastasis of prostate adenocarcinoma cells (PA-III) in L-W ratsCancer Letters, 1996
- Recombinant human erythropoietin stimulates angiogenesis in vitroKidney International, 1995
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences of the United States of America, 1994
- Thalidomide for the Treatment of Chronic Graft-versus-Host DiseaseNew England Journal of Medicine, 1992
- Induction of morphological differentiation in the human leukemic cell line K562 by exposure to thalidomide metabolitesLeukemia Research, 1991
- Tumor Angiogenesis and Metastasis — Correlation in Invasive Breast CarcinomaNew England Journal of Medicine, 1991
- Purification and characterization of hepatic microsomal cytochrome P-450Pharmacology & Therapeutics, 1990